These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 12953137)

  • 1. Early recurrence of rheumatoid arthritis after nonmyeloablative allogeneic blood stem cell transplantation in a patient with multiple myeloma.
    Tapprich C; Fenk R; Schneider P; Bernhardt A; Haas R; Kobbe G
    Bone Marrow Transplant; 2003 Sep; 32(6):629-31. PubMed ID: 12953137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
    Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The first 2 years of clinical experience with peripheral blood stem cell transplantation for various hematological malignancies: results from a single Baskent University Center.
    Ozdogu H; Boga C; Kizilkilic E; Kozanoglu I; Karakus S; Sahin FI; Unalan D; Haberal M
    Transplant Proc; 2007 May; 39(4):1257-60. PubMed ID: 17524948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombotic microangiopathy after combined autografting-allografting for multiple myeloma - report of three cases.
    Kornacker M; Luft T; Ho AD; Schaefer HJ
    Eur J Haematol; 2005 Mar; 74(3):250-3. PubMed ID: 15693795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
    Martino M; Console G; Irrera G; Praticò G; Stelitano C; Callea V; Morabito F; Quartarone E; Musolino C; Piro E; Brugiatelli M; Iacopino P
    Am J Hematol; 2006 Dec; 81(12):973-8. PubMed ID: 16888786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.
    Alyea E; Weller E; Schlossman R; Canning C; Mauch P; Ng A; Fisher D; Gribben J; Freeman A; Parikh B; Richardson P; Soiffer R; Ritz J; Anderson KC
    Bone Marrow Transplant; 2003 Dec; 32(12):1145-51. PubMed ID: 14647268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future strategies in hematopoietic stem cell transplantation for rheumatoid arthritis.
    Burt RK; Barr W; Oyama Y; Traynor A; Slavin S
    J Rheumatol Suppl; 2001 Oct; 64():42-8. PubMed ID: 11642504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular remission of multiple myeloma with cytoreductive autografting followed by a dose-reduced allograft.
    Fujikawa K; Nakaseko C; Cho R; Abe D; Oda K; Tanaka H; Ohwada C; Ozawa S; Takeuchi M; Sakaida E; Shimizu N; Naito M; Nishimura M; Saito Y
    Bone Marrow Transplant; 2007 Nov; 40(10):997-9. PubMed ID: 17724437
    [No Abstract]   [Full Text] [Related]  

  • 10. Autografting followed by a reduced-intensity conditioning unrelated donor cord blood transplantation for a patient with refractory multiple myeloma: successful engraftment with minimal toxicity.
    Ando T; Yujiri T; Tominaga T; Shinya S; Takahashi T; Nomiyama J; Seguchi M; Matsubara A; Fujii Y; Tanizawa Y
    Eur J Haematol; 2005 Feb; 74(2):175-9. PubMed ID: 15654912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
    Kröger N; Perez-Simon JA; Myint H; Klingemann H; Shimoni A; Nagler A; Martino R; Alegre A; Tomas JF; Schwerdtfeger R; Kiehl M; Fauser A; Sayer HG; Leon A; Beyer J; Zabelina T; Ayuk F; San Miguel JF; Brand R; Zander AR
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):698-708. PubMed ID: 15389436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
    Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor lymphocyte infusions for refractory pure red cell aplasia relapsing after both autologous and nonmyeloablative allogeneic peripheral stem cell transplantation.
    Musso M; Porretto F; Crescimanno A; Polizzi V; Scalone R
    Bone Marrow Transplant; 2004 Apr; 33(7):769-71. PubMed ID: 14755320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalan.
    Vela-Ojeda J; García-Ruiz-Esparza MA; Padilla-González Y; Gómez-Almaguer D; Gutiérrez-Aguirre CH; Gómez-Rangel D; Morales-Toquero A; Ruiz-Delgado GJ; Delgado-Lamas JL; Ruiz-Argüelles GJ
    Ann Hematol; 2007 Apr; 86(4):277-82. PubMed ID: 17262193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-centre experience with nonmyeloablative allogeneic stem cell transplantation in patients with multiple myeloma: prolonged remissions induced.
    van Dorp S; Meijer E; van de Donk NW; Dekker AW; Nieuwenhuis K; Minnema MC; Petersen E; Schutgens R; Verdonck LF; Lokhorst HM
    Neth J Med; 2007 May; 65(5):178-84. PubMed ID: 17519513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The treatment of multiple myeloma with an allogeneic peripheral blood stem cell transplantation using a non-myeloablative conditioning regimen].
    Kmonícek M; Jebavý L; Lánská M; Zák P; Malý J; Maisnar V
    Vnitr Lek; 2000 Jul; 46(7):377-83. PubMed ID: 15635796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Second nonmyeloablative allogeneic peripheral blood stem cell transplantation with more immunosuppressive conditioning regimen for the late graft failure of the patient with acute myeloid leukemia].
    Tachikawa Y; Abe Y; Choi I; Ohtsuka R; Nagasawa E; Shibata K; Nishimura J; Nawata H; Muta K
    Fukuoka Igaku Zasshi; 2005 Nov; 96(11):378-82. PubMed ID: 16502857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity.
    Carella AM; Beltrami G; Corsetti MT; Scalzulli P; Carella AM; Musto P
    Haematologica; 2004 Dec; 89(12):1534-6. PubMed ID: 15590410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete remission after myeloablation with bone-seeking 186Re-HEDP and high-dose melphalan followed by autologous stem cell transplantation in a patient with chemorefractory multiple myeloma.
    Wiesmann A; Einsele H; Kanz L; Dohmen BM
    Bone Marrow Transplant; 2005 Jul; 36(1):89-90. PubMed ID: 15895113
    [No Abstract]   [Full Text] [Related]  

  • 20. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.